BioSpace News Archive

Clear Guide Medical proudly announces the FDA clearance for the CLEAR GUIDE SCENERGY computer aided instrument guidance system, alongside the new TP Access Tool with SteriGRID™.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”) today reported financial and operating results for the fourth quarter and financial year 2023.

89bio, Inc. announced that the Company’s Management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 1:40 PM EST and participate in one-on-one investor meetings.

Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, reported the grant of an aggregate of 12,000 restricted stock units of Arcutis’ common stock to two newly hired employees.

NeuroPace, Inc., a medical device company focused on transforming the lives of people living with epilepsy, reported financial results for the fourth quarter and full year ended December 31, 2023.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024.

Vor Bio, a clinical-stage cell and genome engineering company, announced that, effective as of March 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 4,250 shares of Vor Bio’s common stock and restricted stock units representing the right to receive an aggregate of 6,375 shares of Vor Bio’s common stock to two newly hired employees.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, reported financial results for the fourth quarter and full year ended December 31, 2023 and provided recent corporate and clinical updates.

Fate Therapeutics, Inc. announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 40,000 shares of the Company’s common stock at an exercise price per share of $7.74, which was the closing price per share of the Company’s common stock as reported by NASDAQ on the grant effective date of March 1, 2024.

Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2023 and revenue outlook for 2024.